Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
| Revenue (TTM) | $5.01B |
| Gross Profit (TTM) | $3.87B |
| EBITDA | $1.03B |
| Operating Margin | 23.70% |
| Return on Equity | 138.10% |
| Return on Assets | 9.51% |
| Revenue/Share (TTM) | $37.65 |
| Book Value | $26.92 |
| Price-to-Book | 5.82 |
| Price-to-Sales (TTM) | 4.17 |
| EV/Revenue | 3.722 |
| EV/EBITDA | 16.39 |
| Quarterly Earnings Growth (YoY) | 633.00% |
| Quarterly Revenue Growth (YoY) | 16.70% |
| Shares Outstanding | $133.94M |
| Float | $133.63M |
| % Insiders | 0.18% |
| % Institutions | 101.82% |
Volatility is currently expanding
Consensus EPS estimates for 2026 and 2027 revised upward by an average of 6.0% and 4.3%, respectively, during the third quarter. Microsoft Corporation had one of its strongest quarterly stock performances since 1998. Snowflake's strong stock performance was driven by a third consecutive quarter of product revenue growth acceleration.
Alnylam's shares fall 25% despite Q3 beat as slower Amvuttra patient starts and demand concerns weigh on investor sentiment.
Investigation follows the July 30, 2026 disclosure regarding Alnylam Pharmaceuticals, Inc.; investors who lost money may have claims to recover their losses Investigation follows the July 30, 2026 disclosure regarding Alnylam Pharmaceuticals, Inc.; investors who lost money may have claims to recover their losses
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2026 Earnings Call Transcript
Alnylam Pharmaceuticals NASDAQ: ALNY reported third-quarter 2026 global net product revenue of approximately $1.3 billion, up 52% from a year earlier and 10% sequentially, as growth in its transthyretin, or TTR, franchise continued to drive results.
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $16.26 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $2.9 per share a year ago.
While the top- and bottom-line numbers for Alnylam (ALNY) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Alnylam Pharmaceuticals, Inc. (ALNY) RNAi Roundtable: Exon 1 Targeting With Brezosiran for Huntington's Disease Transcript
Alnylam Pharmaceuticals NASDAQ: ALNY outlined early clinical data for brezosiran, an investigational RNA interference therapy for Huntington's disease, reporting dose-dependent reductions in cerebrospinal fluid mutant huntingtin after a single intrathecal dose and plans to begin a placebo-controlled pivotal study in 2027, pending regulatory alignment.
Alnylam Pharmaceuticals, Inc.'s shares remain under pressure. Meanwhile, on October 23, Alnylam reported promising clinical data for brezosiran, its investigational treatment for Huntington's disease. Moreover, second-quarter Amvuttra sales surged 105.7% year-on-year to approximately $1.1 billion.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ALNY and any ticker you trade — then tracks every position and per-strategy win rate.
